GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity

LA JOLLA, CA, April 29, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that its abstracts have been accepted for presentation at the 14^th International Congress on Autoimmunity being held May 17-20, 2024 in Ljubljana, Slovenia.

Details of the presentations are as follows:

Oral Presentation

Title: Tissue Residency and Innate-Like Features Play Important Roles in CD8 Treg-Mediated Immune Regulation
Presenter: Vipin Kumar Chaturvedi, PhD, Chief Scientific Officer of GRI Bio
Session: 0590 – Oral Discussions 07: Update in Pathogenesis of Autoimmune Diseases
Date and Time: Saturday, May 18, 2024 at 1:10 PM (GMT+2)

Parallel Session

Title: Type 2 NKT Cells Directed Immune Regulatory Mechanism in Lupus Nephritis
Presenter: Vipin Kumar Chaturvedi, PhD, Chief Scientific Officer of GRI Bio
Session: 1180 – Parallel Session 24: Mechanisms in Autoimmunity Part 2
Date and Time: Monday, May 20, 2024 at 2:45 PM (GMT+2)

For more information about the 14^th International Congress on Autoimmunity, please visit the conference website here.

About GRI Bio, Inc.

GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. iNKT cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.